Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

2.

Peroxisome proliferator-activated receptors and the control of inflammation.

Cabrero A, Laguna JC, Vázquez M.

Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):243-8. Review.

PMID:
14561188
3.

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.

Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B.

Arterioscler Thromb Vasc Biol. 2006 May;26(5):977-86. Epub 2006 Jan 19. Review.

4.

Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis.

Gouni-Berthold I, Krone W.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec;5(6):513-23. Review.

PMID:
16503871
5.

Phytoestrogens and the metabolic syndrome.

Jungbauer A, Medjakovic S.

J Steroid Biochem Mol Biol. 2014 Jan;139:277-89. doi: 10.1016/j.jsbmb.2012.12.009. Epub 2013 Jan 11. Review.

PMID:
23318879
6.

PPARα as a therapeutic target in inflammation-associated diseases.

Gervois P, Mansouri RM.

Expert Opin Ther Targets. 2012 Nov;16(11):1113-25. doi: 10.1517/14728222.2012.715633. Epub 2012 Aug 27. Review.

PMID:
22925108
7.

Macrophage-derived lipid agonists of PPAR-α as intrinsic controllers of inflammation.

Pontis S, Ribeiro A, Sasso O, Piomelli D.

Crit Rev Biochem Mol Biol. 2016;51(1):7-14. doi: 10.3109/10409238.2015.1092944. Epub 2015 Nov 20. Review.

PMID:
26585314
8.

Biochanin a: understanding the complexities in the paradoxical drug-drug interaction potential.

Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):119-25. doi: 10.1007/s13318-015-0279-0. Review.

PMID:
25903969

Supplemental Content

Support Center